Related references
Note: Only part of the references are listed.Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo
Stefania Lymperi et al.
BLOOD (2011)
Repression of Vascular Endothelial Growth Factor Expression by the Runt-Related Transcription Factor 1 in Acute Myeloid Leukemia
Arja ter Elst et al.
CANCER RESEARCH (2011)
Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate
Jonas Abrahamsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vascular Endothelial Growth Factor A Isoform mRNA Expression in Pediatric Acute Myeloid Leukemia
R. C. Kruizinga et al.
PEDIATRIC BLOOD & CANCER (2011)
High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
Alida C. Weidenaar et al.
CELLULAR ONCOLOGY (2011)
High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia
Hendrik J. M. de Jonge et al.
BLOOD (2010)
Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations
Heidrun Gerr et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Neil R. Smith et al.
CLINICAL CANCER RESEARCH (2010)
Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head
Jung Min Hong et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ligand-Stimulated VEGFR2 Signaling is Regulated by Co-Ordinated Trafficking and Proteolysis
Alexander F. Bruns et al.
TRAFFIC (2010)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005
Asa Rangert Derolf et al.
BLOOD (2009)
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway
Ming-Hsien Chien et al.
CARCINOGENESIS (2009)
The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia
B. Wegiel et al.
LEUKEMIA (2009)
Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol
Sergio Gallegos-Castorena et al.
LEUKEMIA & LYMPHOMA (2009)
Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor
Norikazu Imai et al.
LEUKEMIA RESEARCH (2009)
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche
Cristina Lo Celso et al.
NATURE (2009)
Independent prognostic factors for AML outcome
D. Grimwade et al.
Hematology-American Society of Hematology Education Program (2009)
Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche
Yoshiaki Kubota et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
Pascale Flandrin et al.
CELL STRESS & CHAPERONES (2008)
Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia
Hendrik J. M. de Jonge et al.
CLINICAL CANCER RESEARCH (2008)
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism
Qian Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF
H. J. Knowles et al.
JOURNAL OF PATHOLOGY (2008)
Human mesenchymal stem cells as a stabte source of VEGF-producing cells
Harumi Kagiwada et al.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2008)
Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia
Ruediger Liersch et al.
LEUKEMIA RESEARCH (2008)
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia
Hsin-An Hou et al.
LEUKEMIA RESEARCH (2008)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia
Kalindi Parmar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice
M. Ninomiya et al.
LEUKEMIA (2007)
Autocrine VEGF loops, signaling pathways, and acute leukemia regulation
Rita Fragoso et al.
LEUKEMIA & LYMPHOMA (2007)
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity
L. Zahiragic et al.
LEUKEMIA (2007)
STAT3 mediates bone marrow mesenchymal stem cell VEGF production
Meijing Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt
Norikazu Imai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
Mariano Monzo et al.
BLOOD (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Bone-marrow haematopoietic-stem-cell niches
A Wilson et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML
A Hiramatsu et al.
LEUKEMIA & LYMPHOMA (2006)
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
G. J. Roboz et al.
LEUKEMIA (2006)
Phosphorylated KDR can be located in the nucleus of neoplastic cells
C Blazquez et al.
CELL RESEARCH (2006)
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line
S Coppola et al.
CELL DEATH AND DIFFERENTIATION (2006)
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
MJ Kiel et al.
CELL (2005)
HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun
H Schepers et al.
EXPERIMENTAL HEMATOLOGY (2005)
The biology of vascular endothelial growth factors
T Tammela et al.
CARDIOVASCULAR RESEARCH (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice
I Kodama et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bone marrow microvessel density and it's prognostic significance in AML
W Rabitsch et al.
LEUKEMIA & LYMPHOMA (2004)
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
MI Koukourakis et al.
LUNG CANCER (2004)
Vascular endothelial growth factor and angiogenesis
A Hoeben et al.
PHARMACOLOGICAL REVIEWS (2004)
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:: Therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
JE Karp et al.
CLINICAL CANCER RESEARCH (2004)
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways
SCR Santos et al.
BLOOD (2004)
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
W Fiedler et al.
BLOOD (2003)
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
H Gerhardt et al.
JOURNAL OF CELL BIOLOGY (2003)
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
G Schuch et al.
BLOOD (2002)
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
A Aguayo et al.
CANCER (2002)
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
T Padró et al.
LEUKEMIA (2002)
VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition
S Dias et al.
BLOOD (2002)
Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A
MML Deckers et al.
ENDOCRINOLOGY (2002)
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
S Dias et al.
BLOOD (2002)
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
RM Mesters et al.
BLOOD (2001)
Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor
ESJM de Bont et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts
B Foss et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Share Paper
